GEN Exclusives

More »

GEN News Highlights

More »
May 2, 2012

Sanofi Pasteur’s Quadrivalent Flu Vaccine Succeeds in Phase III Pediatric Study

  • Sanofi Pasteur reported positive data from a Phase III study comparing its quadrivalent influenza vaccine (QIV) to the firm’s approved trivalent vaccine Fluzone®, in infants and children aged 6 months to 8 years. The trial included over 4,300 children, and demonstrated the noninferiority of QIV when compared with vaccination using either the licensed trivalent inactivated vaccine (TIV) Fluzone, which contains two influenza A strains and the Victoria-lineage B strain, or a TIV containing the two licensed A strains plus the alternate (Yamagata) B lineage strain.

    Seasonal trivalent influenza vaccines currently contain two A strains and one B strain, but two distinct B lineage strains have co-circulated over the last decade with varying prevlance, which makes it hard to predict which will predominate in a given year, Sanofi Pasteur explains. Moreover, the firm claims, about 50% of the time the B-lineage strain selected for the annual vaccine hasn’t matched the strain predominating during that season.

    “We believe that a quadrivalent Fluzone vaccine could provide an important public health benefit for people of all ages by providing coverage against an extra B virus strain of influenza,” comments David Greenberg, M.D., senior director for U.S. scientific and medical affairs at Sanofi Pasteur. “Influenza B is responsible for a substantial burden of disease and influenza-associated complications and hospitalizations in children.” 


Add a comment

  • You must be signed in to perform this action.
    Click here to Login or Register for free.
    You will be taken back to your selected item after Login/Registration.

Related content

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...

Unable to get Jobs Listings.

More »

GEN Poll

More » Poll Results »

Biosimilars

Compared to the original biologics, do you think biosimilars run the risks of being less effective and causing more side effects?